| scholarly article | Q13442814 |
| P2093 | author name string | Lu Wang | |
| Arthur M Brown | |||
| Eckhard Ficker | |||
| Yuri A Kuryshev | |||
| Adrienne T Dennis | |||
| Barbara A Wible | |||
| Carlos Obejero-Paz | |||
| Peter Hawryluk | |||
| P433 | issue | 1 | |
| P921 | main subject | arsenic | Q871 |
| P304 | page(s) | 33-44 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Mechanisms of arsenic-induced prolongation of cardiac repolarization | |
| P478 | volume | 66 |
| Q38646540 | (-)-Epicatechin rescues the As2 O3 -induced HERG K(+) channel deficiency possibly through upregulating transcription factor SP1 expression. |
| Q37480106 | A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays |
| Q39443606 | A history of the role of the hERG channel in cardiac risk assessment |
| Q36409452 | A search to predict potential for drug-induced cardiovascular toxicity |
| Q39153130 | Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels. |
| Q38112653 | An overview of QT interval assessment in safety pharmacology |
| Q37529611 | Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity |
| Q39851183 | Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5. |
| Q33160342 | Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG. |
| Q36150536 | Antimalarial drugs: QT prolongation and cardiac arrhythmias |
| Q36313699 | Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends |
| Q36750972 | Arsenic exposure from drinking water and QT-interval prolongation: results from the Health Effects of Arsenic Longitudinal Study |
| Q37890950 | Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction |
| Q36230637 | Arsenic trioxide induces the apoptosis of human breast cancer MCF-7 cells through activation of caspase-3 and inhibition of HERG channels |
| Q43272891 | Arsenic trioxide modulates the central snail neuron action potential. |
| Q39243034 | Arsenic trioxide toxicity in H9c2 myoblasts--damage to cell organelles and possible amelioration with Boerhavia diffusa |
| Q34588761 | Arsenic trioxide: safety issues and their management |
| Q37401684 | Association between low-level environmental arsenic exposure and QT interval duration in a general population study |
| Q58969794 | Association of low-moderate urine arsenic and QT interval: Cross-sectional and longitudinal evidence from the Strong Heart Study |
| Q38944823 | Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies |
| Q39854998 | Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells |
| Q47828303 | Blockade of the human ether-a-go-go-related gene potassium channel by ketamine. |
| Q39052111 | Blockage of hERG current and the disruption of trafficking as induced by roxithromycin |
| Q38313870 | Cancer chemotherapy and cardiac arrhythmias: a review. |
| Q54997821 | Cancer drugs and QT prolongation: weighing risk against benefit. |
| Q38854252 | Cardiac Delayed Rectifier Potassium Channels in Health and Disease |
| Q34571555 | Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs |
| Q24615347 | Cardiac applications for human pluripotent stem cells |
| Q37098991 | Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview |
| Q38837706 | Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative. |
| Q35538844 | Cardiovascular disease and arsenic exposure in Inner Mongolia, China: a case control study |
| Q38135772 | Cardiovascular effects of arsenic: clinical and epidemiological findings. |
| Q24295274 | Cell surface expression of human ether-a-go-go-related gene (hERG) channels is regulated by caveolin-3 protein via the ubiquitin ligase Nedd4-2 |
| Q34786459 | Cellular basis of drug-induced torsades de pointes |
| Q33240320 | Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig. |
| Q35790980 | Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study |
| Q48353831 | Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes. |
| Q50628884 | Clenbuterol Attenuates hERG Channel by Promoting the Mature Channel Degradation. |
| Q40061024 | Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome |
| Q36054425 | Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. |
| Q38304968 | Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels |
| Q37580457 | Delayed rectifier K(+) currents and cardiac repolarization. |
| Q46466473 | Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: importance of the choice of species, type of cardiac tissue and perfusion time |
| Q34358104 | Drug-Induced Long QT Syndrome |
| Q36886266 | Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias |
| Q33949538 | Drug-induced QT interval prolongation: mechanisms and clinical management |
| Q37734559 | Drug-induced hERG block and long QT syndrome |
| Q36054408 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. |
| Q41856022 | Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? |
| Q36029828 | Drugs, QT interval prolongation and ICH E14: the need to get it right |
| Q36289359 | Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead |
| Q64974057 | Dual effects of arsenic trioxide on tumor cells and the potential underlying mechanisms. |
| Q47660741 | Effect of chronic arsenic exposure from drinking waters on the QT interval and transmural dispersion of repolarization |
| Q33328530 | Electrophysiological and fluorescence microscopy studies with HERG channel/EGFP fusion proteins |
| Q35083164 | Endocytosis of HERG is clathrin-independent and involves arf6. |
| Q39804262 | Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines |
| Q43123680 | HERG biosynthesis: the positive influence of negative charge |
| Q40410928 | HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk |
| Q33915930 | HERG1 channelopathies |
| Q35769756 | High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds |
| Q39634258 | High-content screening of drug-induced cardiotoxicity using quantitative single cell imaging cytometry on microfluidic device |
| Q33661427 | Hsp40 chaperones promote degradation of the HERG potassium channel |
| Q37327572 | Hypoxia inhibits maturation and trafficking of hERG K(+) channel protein: Role of Hsp90 and ROS. |
| Q36150565 | ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis |
| Q33653994 | Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance |
| Q39971749 | Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells |
| Q35941355 | Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs |
| Q36018689 | In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials |
| Q46433901 | Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation |
| Q39896175 | Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum |
| Q37691207 | KCNH2 pharmacogenomics summary |
| Q37960089 | Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology |
| Q33789857 | L-type calcium current (ICa,L) and inward rectifier potassium current (IK1) are involved in QT prolongation induced by arsenic trioxide in rat. |
| Q64094617 | Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology |
| Q36335258 | Long QT syndrome: reduced repolarization reserve and the genetic link |
| Q36212952 | Mechanism and pharmacological rescue of berberine-induced hERG channel deficiency |
| Q50994594 | Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism. |
| Q37038711 | Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond |
| Q36675819 | Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells |
| Q44224074 | Methodological innovations expand the safety pharmacology horizon |
| Q38943978 | MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel |
| Q42078619 | Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels |
| Q92239237 | Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells |
| Q35688489 | Molecular determinants of pentamidine-induced hERG trafficking inhibition |
| Q36545039 | Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. |
| Q28077303 | Molecular pathogenesis of long QT syndrome type 2 |
| Q39727797 | Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine |
| Q37008418 | On the relationship among QT interval, atrial fibrillation, and torsade de pointes |
| Q34509473 | Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome |
| Q31147309 | Pentamidine reduces hERG expression to prolong the QT interval |
| Q51104877 | Points to consider emerging from a mini-workshop on cardiac safety: assessing torsades de pointes liability. |
| Q39032990 | Polyphenol-rich apple (Malus domestica L.) peel extract attenuates arsenic trioxide induced cardiotoxicity in H9c2 cells via its antioxidant activity |
| Q38784935 | Proarrhythmic risk assessment using conventional and new in vitro assays |
| Q35048830 | Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome |
| Q35572883 | QTc prolongation assessment in anticancer drug development: clinical and methodological issues |
| Q33916392 | R-type calcium channels are crucial for semaphorin 3A-induced DRG axon growth cone collapse |
| Q40760443 | Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel |
| Q37354231 | Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice |
| Q33911355 | Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. |
| Q37230993 | Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents |
| Q37171823 | Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective |
| Q39435268 | Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue |
| Q37909132 | Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview |
| Q36387356 | Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome |
| Q41457623 | Synchronization in the Heart Rate and the Vasomotion in Rat Aorta: Effect of Arsenic Trioxide. |
| Q56855345 | The Assessment of QT/QTc Interval Prolongation in Clinical Trials: A Regulatory Perspective |
| Q37358300 | The Protective Role of Resveratrol against Arsenic Trioxide-Induced Cardiotoxicity |
| Q42704539 | The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency. |
| Q89736832 | Thioridazine Induces Cardiotoxicity via Reactive Oxygen Species-Mediated hERG Channel Deficiency and L-Type Calcium Channel Activation |
| Q27008208 | Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects |
| Q34568155 | Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy |
| Q37387802 | Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational defect at the plasma membrane |
| Q37521165 | Up-regulation of hERG K⁺ channels by B-RAF. |
| Q42703625 | Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency |
| Q57100336 | Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates |
| Q43487048 | hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine |
| Q33845924 | hERG-related drug toxicity and models for predicting hERG liability and QT prolongation |
Search more.